ChemICare has patented and preclinically developed small molecules unique in their capacity to modulate calcium ions uptake in cellular processes. The aforementioned small molecules are able to restore calcium to physiological levels in those clinical settings where there is an alteration of SOCE.
These disorders include rare diseases such as Tubular Aggregate Myopathies (TAM) and Duchenne muscular Dystrophy (DMD), but also diseases with higher incidence like Acute pancreatitis (AP) and Rheumatoid Arthritis (RA).
ChemICare combines the skills of experts in medicinal chemistry, pharmacology and biotechnology with the aim to develop and market small molecules biologically active in modulating the calcium ions uptake.
Our solution relies on a technology named click chemistry that allows the parallel preparation of a library of small molecules and the rapid and effective exploration of the chemical space. This approach allows to greatly accelerate the drug discovery process and to easily refine the identified hit compounds in order to overcome any pharmacokinetic and/or pharmacodynamic need occurring during the pre-clinical development.
ChemICare therapeutic product (CIC-39) is a small molecule that acts as a negative modulator of SOCE. CIC-39 effectively reduces aberrant calcium entry and restores cytosolic calcium to physiological levels, both in in vitro and in vivo models.
ChemICare’s mission aims to create value taking our drug through the preclinical development stages in order to reach the regulatory preclinical study package and obtain the IND/CTA in mind-2023. This allow ChemICare to license out the specific therapeutic pipelines to a big or medium-sized pharmaceutical company that will complete the clinical trials and commercialize the drug.

Collaboration and partnership

1. University of Piemonte Orientale (UPO), Department of Pharmaceutical Sciences (DSF)
Joint development agreement with Prof. Armando Genazzani.
Agreement aimed to study the efficacy of ChemICare’s patented molecules, in particular CIC-39, in specific mouse model of tubular aggregate myopathy (KI-STIM1I115F)
2. University of Piemonte Orientale (UPO), Department of Translational Medicine (DIMET) Joint Development Agreement with Prof. Nicoletta Filigheddu.
Agreement aimed to study the efficacy of ChemICare’s patented molecules, in particular CIC-39, in specific mouse model of Duchenne muscular dystrophy (mdx)
3. Bio4Dreams SPA
Incubation and Investment.
Bio4Dreams invested in ChemICare as minority shareholder. Moreover, ChemICare has signed an indubation agreement with Bio4Dreams for delivery of a qwide range of services related to the operational, managerial and business development activities of the company.